ResMed Inc. (RMD), a global leader in digital health and cloud-connected medical devices for sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases, reported strong financial performance in the third quarter of fiscal year 2024. The company reported a 7% increase in constant currency terms leading to group revenue of $1.2 billion, with notable growth in device and mask sales.
The press conference highlighted ResMed’s strategic focus on expanding the sleep and respiratory health market and investing in digital health technology to improve patient outcomes.
Strengths
ResMed’s revenue in the third quarter of fiscal 2014 reached $1.2 billion, an increase of 7 percent in constant currency terms. Device sales grew 5 percent, while masks and accessories grew recorded growth of 10% compared to the previous year. Gross margin improved by 240 basis points, reaching 58.5%. Net income and non-GAAP diluted earnings per share both increased by 27%. The company declared a quarterly dividend of $0.48 per share and continued its share repurchase program. ResMed is investing in marketing and research and development to drive growth and plans to expand its presence globally.
Company prospects
ResMed aims to leverage consumer and Big Pharma technology trends to grow the healthcare market. The company is focusing on the non-invasive ventilation market with its AirSense 11 and AirCurve 11 platforms. Plans are in place to continue share repurchases, reinvest in R&D, reduce debt and consider strategic acquisitions.Third Party Announcement. This is not an offer or recommendation by Investing.com. Consult the information Who or remove ads.
Bearish highlights
Potential headwinds from conflict in the Middle East could negatively impact fourth quarter gross margin by 30-50 basis points.
Bullish strengths
Strong device growth in the US, Canada and Latin America, with continued new patient starts. Significant improvement in gross margins due to cost reduction and stable operations. Positive real-world data with 660,000 patients showing improvement in supply and adhesion. No significant pricing pressure from Philips in competitive markets.
Shortcomings
No specific details were provided on the gross margin improvement expected for fiscal 2025.
Highlights from the questions and answers
Philips’ return to some markets has not dented ResMed’s market share as a global leader. Philips competes with local players and faces severe restrictions in the U.S. due to a consent decree. ResMed remains confident in its ability to compete and take market share away from Philips.
ResMed’s third quarter highlighted its strong financial health and strategic initiatives to expand its market presence. With the introduction of new products such as the AirFit F40 mask and a focus on digital health solutions, the company is well positioned to continue its growth trajectory. Despite potential headwinds, ResMed’s commitment to innovation and global expansion reflects a positive outlook for the future.
Insights from InvestingPro
ResMed Inc. (RMD) has demonstrated a solid financial trajectory, as per the latest data from InvestingPro. With a market capitalization of $31.52 billion, the company is a significant player in the medical device and digital health industry. The robust revenue growth of 14.16% over the past twelve months, starting from the third quarter of 2024, underlines the company’s ability to effectively expand its market presence.
Third Party Advertisement. This is not an offer or recommendation by Investing.com. Consult the information Who or remove ads.
InvestingPro Tips highlight that ResMed has increased its dividend for 13 consecutive years, demonstrating a reliable commitment to returning value to shareholders. This is especially noteworthy for investors looking for stable income streams. Furthermore, 6 analysts have revised earnings upwards for the coming period, indicating positive sentiment on the company’s future performance.
Key InvestingPro Data metrics to consider:
P/E ratio (adjusted): 31.81, which suggests that investors are willing to pay a higher price for every dollar of earnings, which can be attributed to the company’s growth prospects and market leadership.Growth Revenue: The company’s revenue grew 14.16% over the trailing twelve months as of Q3 2024, highlighting its successful expansion and product adoption. 1-Week Total Price Return: A significant return of 20.91% over the past week reflects strong investor confidence and the market’s reaction to recent developments or company performance.
Investors interested in deeper analysis can find additional InvestingPro recommendations for ResMed on including insights into the company’s valuation multiples and debt management. To explore these tips and take advantage of the insights offered, use the coupon code PRONEWS24 to get an additional 10% discount on an annual or two-year subscription to Pro and Pro+. Thanks to the 17 additional tips listed in InvestingPro subscribers can gain a comprehensive understanding of ResMed’s financial health and investment potential.
Third Party Advertisement. This is not an offer or recommendation by Investing.com. Consult the information Who or remove ads.
This article was generated and translated with the support of artificial intelligence and reviewed by an editor. For further information, please see our T&Cs.